Airsculpt Technologies (AIRS)

$5.61

+0.58

(+11.53%)▲

Market is closed - opens 8 PM, 04 Dec 2023

Insights on Airsculpt Technologies

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 55.70M → 46.79M (in $), with an average decrease of 16.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 1.77M → -1.66M (in $), with an average decrease of 193.9% per quarter

Performance

  • $4.98
    $5.62
    $5.61
    downward going graph

    11.22%

    Downside

    Day's Volatility :11.38%

    Upside

    0.18%

    downward going graph
  • $2.96
    $9.94
    $5.61
    downward going graph

    47.24%

    Downside

    52 Weeks Volatility :70.22%

    Upside

    43.56%

    downward going graph

Returns

PeriodAirsculpt TechnologiesSector (Health Care)Index (Russel 2000)
3 Months
-28.08%
-1.3%
0.0%
6 Months
-31.59%
1.2%
0.0%
1 Year
52.86%
-5.7%
-6.5%
3 Years
-64.69%
18.2%
-3.8%

Highlights

Market Capitalization
311.4M
Book Value
$1.48
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.13
Wall Street Target Price
8.15
Profit Margin
-3.76%
Operating Margin TTM
2.05%
Return On Assets TTM
0.87%
Return On Equity TTM
-9.06%
Revenue TTM
189.0M
Revenue Per Share TTM
3.35
Quarterly Revenue Growth YOY
20.3%
Gross Profit TTM
110.5M
EBITDA
12.5M
Diluted Eps TTM
-0.13
Quarterly Earnings Growth YOY
2.0
EPS Estimate Current Year
0.02
EPS Estimate Next Year
0.21
EPS Estimate Current Quarter
-0.02
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    72%Buy
    27%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Airsculpt Technologies(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 45.28%

Current $5.61
Target $8.15

Company Financials

FY19Y/Y Change
Revenue
41.2M
-
Net Income
-5.1M
-
Net Profit Margin
-12.34%
-
FY20Y/Y Change
Revenue
62.8M
↑ 52.21%
Net Income
5.8M
↓ 213.03%
Net Profit Margin
9.16%
↑ 21.5%
FY21Y/Y Change
Revenue
133.3M
↑ 112.4%
Net Income
10.6M
↑ 83.5%
Net Profit Margin
7.91%
↓ 1.25%
FY22Y/Y Change
Revenue
168.8M
↑ 26.61%
Net Income
-14.7M
↓ 239.12%
Net Profit Margin
-8.7%
↓ 16.61%
Q2 FY22Q/Q Change
Revenue
49.7M
↑ 25.57%
Net Income
583.0K
↓ 184.13%
Net Profit Margin
1.17%
↑ 2.92%
Q3 FY22Q/Q Change
Revenue
38.9M
↓ 21.67%
Net Income
-7.4M
↓ 1365.35%
Net Profit Margin
-18.97%
↓ 20.14%
Q4 FY22Q/Q Change
Revenue
40.7M
↑ 4.66%
Net Income
-7.2M
↓ 2.51%
Net Profit Margin
-17.67%
↑ 1.3%
Q1 FY23Q/Q Change
Revenue
45.8M
↑ 12.55%
Net Income
-14.0K
↓ 99.81%
Net Profit Margin
-0.03%
↑ 17.64%
Q2 FY23Q/Q Change
Revenue
55.7M
↑ 21.59%
Net Income
1.8M
↓ 12785.71%
Net Profit Margin
3.19%
↑ 3.22%
Q3 FY23Q/Q Change
Revenue
46.8M
↓ 16.0%
Net Income
-1.7M
↓ 193.86%
Net Profit Margin
-3.56%
↓ 6.75%
FY19Y/Y Change
Total Assets
171.5M
-
Total Liabilities
51.1M
-
FY20Y/Y Change
Total Assets
179.6M
↑ 4.73%
Total Liabilities
55.9M
↑ 9.44%
FY21Y/Y Change
Total Assets
200.6M
↑ 11.66%
Total Liabilities
117.0M
↑ 109.22%
FY22Y/Y Change
Total Assets
200.8M
↑ 0.1%
Total Liabilities
130.0M
↑ 11.08%
Q2 FY22Q/Q Change
Total Assets
218.8M
↑ 5.57%
Total Liabilities
121.3M
↑ 3.39%
Q3 FY22Q/Q Change
Total Assets
193.9M
↓ 11.36%
Total Liabilities
121.4M
↑ 0.09%
Q4 FY22Q/Q Change
Total Assets
200.8M
↑ 3.53%
Total Liabilities
130.0M
↑ 7.04%
Q1 FY23Q/Q Change
Total Assets
209.5M
↑ 4.36%
Total Liabilities
134.3M
↑ 3.31%
Q2 FY23Q/Q Change
Total Assets
217.3M
↑ 3.71%
Total Liabilities
135.8M
↑ 1.13%
Q3 FY23Q/Q Change
Total Assets
204.1M
↓ 6.06%
Total Liabilities
119.9M
↓ 11.69%
FY19Y/Y Change
Operating Cash Flow
4.9M
-
Investing Cash Flow
-4.4M
-
Financing Cash Flow
-783.0K
-
FY20Y/Y Change
Operating Cash Flow
14.0M
↑ 182.64%
Investing Cash Flow
-3.7M
↓ 16.9%
Financing Cash Flow
-5.0M
↑ 540.74%
FY21Y/Y Change
Operating Cash Flow
26.6M
↑ 90.82%
Investing Cash Flow
-7.1M
↑ 92.9%
Financing Cash Flow
-4.5M
↓ 9.33%
FY22Y/Y Change
Operating Cash Flow
24.4M
↓ 8.21%
Investing Cash Flow
-12.9M
↑ 81.58%
Financing Cash Flow
-27.3M
↑ 499.19%
Q2 FY22Q/Q Change
Operating Cash Flow
10.4M
↑ 46.86%
Investing Cash Flow
-1.9M
↓ 56.36%
Financing Cash Flow
-509.0K
↓ 44.91%
Q3 FY22Q/Q Change
Operating Cash Flow
329.0K
↓ 96.84%
Investing Cash Flow
-4.6M
↑ 145.95%
Financing Cash Flow
-23.4M
↑ 4496.27%
Q4 FY22Q/Q Change
Operating Cash Flow
6.6M
↑ 1918.24%
Investing Cash Flow
-2.2M
↓ 52.15%
Financing Cash Flow
-2.4M
↓ 89.62%
Q1 FY23Q/Q Change
Operating Cash Flow
6.2M
↓ 6.34%
Investing Cash Flow
-3.8M
↑ 73.8%
Financing Cash Flow
-737.0K
↓ 69.66%
Q2 FY23Q/Q Change
Operating Cash Flow
12.2M
↑ 96.75%
Investing Cash Flow
-2.2M
↓ 43.36%
Financing Cash Flow
-579.0K
↓ 21.44%

Technicals Summary

Sell

Neutral

Buy

Airsculpt Technologies is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Airsculpt Technologies
Airsculpt Technologies
-6.19%
-31.59%
52.86%
-64.69%
-64.69%
Fresenius Medical Care Ag & Co. Kgaa
Fresenius Medical Care Ag & Co. Kgaa
20.12%
-5.08%
26.5%
-50.8%
-50.54%
Hca Holdings, Inc.
Hca Holdings, Inc.
10.72%
-7.99%
5.58%
65.37%
72.51%
Universal Health Services Inc.
Universal Health Services Inc.
9.19%
1.65%
6.46%
4.31%
0.53%
Davita Healthcare Partners Inc.
Davita Healthcare Partners Inc.
34.06%
5.64%
40.31%
-3.74%
57.14%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Airsculpt Technologies
Airsculpt Technologies
100.0
NA
NA
0.02
-0.09
0.01
0.0
1.48
Fresenius Medical Care Ag & Co. Kgaa
Fresenius Medical Care Ag & Co. Kgaa
23.89
23.89
1.06
1.95
0.04
0.02
0.03
47.74
Hca Holdings, Inc.
Hca Holdings, Inc.
12.45
12.45
1.37
18.2
0.21
0.11
0.01
-9.21
Universal Health Services Inc.
Universal Health Services Inc.
14.41
14.41
1.87
10.3
0.11
0.05
0.01
88.85
Davita Healthcare Partners Inc.
Davita Healthcare Partners Inc.
15.41
15.41
0.86
7.83
0.34
0.05
0.11
13.13
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Airsculpt Technologies
Airsculpt Technologies
Buy
$311.4M
-64.69%
100.0
-3.76%
Fresenius Medical Care Ag & Co. Kgaa
Fresenius Medical Care Ag & Co. Kgaa
Hold
$11.8B
-50.54%
23.89
2.31%
Hca Holdings, Inc.
Hca Holdings, Inc.
Buy
$67.5B
72.51%
12.45
9.05%
Universal Health Services Inc.
Universal Health Services Inc.
Hold
$9.4B
0.53%
14.41
4.82%
Davita Healthcare Partners Inc.
Davita Healthcare Partners Inc.
Hold
$9.1B
57.14%
15.41
5.11%

Institutional Holdings

  • Vesey Street Capital Partners, L.L.C.

    51.64%

  • SW Investment Management LLC

    6.01%

  • Balyasny Asset Management LLC

    1.45%

  • BlackRock Inc

    1.22%

  • Bandera Partners LLC

    1.10%

  • Vanguard Group Inc

    0.95%

Company Information

at elite body sculpture we focus on body contouring. using our minimally invasive and patented airsculpt® technology, our procedures are geared to make healing faster with less bruising and less trauma to the area being treated. our commitment is to provide the very best possible results for each patient, using the most up to date and advanced technology.

Organization
Airsculpt Technologies
Employees
291
CEO
Dr. Aaron J. Rollins M.D.
Industry
Healthcare

Discover More

FAQs